Denikitug for Colorectal Cancer

This trial explores a new drug, Denikitug (GS-1811), to evaluate its effectiveness for individuals with advanced colorectal cancer lacking a specific genetic trait (microsatellite stability). The study tests Denikitug alone and with other cancer treatments to determine if it can enhance the response rate. Suitable participants have colorectal cancer that has spread or returned and have tried up to two unsuccessful treatments. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you must stop taking your current medications, but it mentions that you should not have had certain cancer treatments recently. It's best to discuss your current medications with the trial team.

Research has shown that Denikitug (GS-1811) possesses a manageable safety profile. In earlier studies, participants generally tolerated the drug well, experiencing only mild to moderate side effects. These studies aimed to determine the safest dose and demonstrated that Denikitug is generally well-tolerated.

When combined with nivolumab, studies focused on safety and found this combination promising, with a safety profile similar to Denikitug alone. Most participants experienced manageable and non-severe side effects.

The combination of Denikitug with trifluridine-tipiracil and bevacizumab has also been studied. Trifluridine-tipiracil and bevacizumab, already approved by the FDA for treating colorectal cancer, have a known safety profile. When combined with Denikitug, this treatment was similarly well-tolerated, with expected side effects.

Denikitug (GS-1811) is unique because it targets colorectal cancer differently than current standard treatments like bevacizumab (BVZ) and trifluridine-tipiracil (FTD-TPI). Unlike these conventional therapies, Denikitug is an experimental antibody designed to be administered intravenously, either alone or in combination with other drugs like nivolumab (NIVO) or BVZ and FTD-TPI, offering a new approach to treatment. Researchers are excited because Denikitug may provide enhanced effectiveness by employing a novel mechanism of action that could potentially improve outcomes for patients with colorectal cancer.

This trial will evaluate Denikitug (GS-1811) in various treatment combinations for colorectal cancer. Studies have shown that Denikitug targets a specific protein called CCR8, which aids the immune system in fighting cancer by reducing certain immune cells that protect the tumor. Research suggests this can lead to strong anti-tumor effects, at least in early tests. In this trial, some participants will receive Denikitug with nivolumab, a drug that helps the immune system identify and attack cancer cells and has shown promise in treating other cancers. Another group will receive Denikitug with trifluridine-tipiracil and bevacizumab, which have been effective in treating colorectal cancer; adding Denikitug may enhance these results. While these findings are promising, more research is needed to confirm Denikitug's effectiveness in humans.¹²⁴⁶⁷